dr. ledermann on parp inhibitors in maintenance therapy for ovarian cancer
Published 5 years ago • 425 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
7:10
jonathan a ledermann – maintenance treatment for recurrent ovarian carcinoma
-
1:20
dr. ledermann on rationale for ariel3 trial in ovarian cancer
-
4:17
maintenance therapy in ovarian cancer: parp inhibitors
-
1:26
parp inhibitors for maintenance therapy in ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
0:58
dr. ledermann on systemic treatment for rare gynecologic tumors
-
1:14
dr. ledermann on the treatment landscape for rare gynecologic cancers
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
59:02
parp inhibitors as first-line maintenance therapy in ovarian cancer
-
5:55
maintenance therapy: parp inhibitor or bevacizumab
-
1:19
dr. ledermann on phase iii ariel3 results in ovarian cancer
-
2:15
toxicities associated with rucaparib for the treatment of ovarian cancer
-
7:38
parp maintenance therapy in recurrent ovarian cancer
-
7:56
maintenance therapy in ovarian cancer
-
8:41
parp inhibitors for ovarian cancer: use of olaparib
-
3:06
recurrent ovarian cancer: choosing a parp inhibitor
-
0:45
dr. coffman on safety concerns with parp inhibitors in ovarian cancer